Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
Total raised: $30M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.06.2024 | Seed | $18M | - |
| 06.12.2023 | Seed | $12M | - |
Mentions in press and media 5
| Date | Title | Description |
| 02.07.2024 | Ability Biologics: Revolutionizing Antibody Therapeutics | Ability Biologics, a Montreal-based cell targeting company, recently closed an impressive $18 million in seed funding. Led by CEO Giles Day, the company is on a mission to develop potent and selective antibody therapeutics for areas of grea... |
| 28.06.2024 | Ability Biologics: Cell Targeting Company Raises $18 Million In Seed Funding | Ability Biologics announced the final closing of its seed funding, raising a total of $18 million, a financing round led by founding investor Amplitude Ventures. Amplitude is joined by the Fonds de solidarité FTQ, Investissement Québec, Cha... |
| 18.06.2024 | Ability Biologics Closes US $18M Seed Funding | Giles Day, Co-Founder and CEO (CNW Group/Ability Biologics) Ability Biologics, a Montreal, Canada-based cell targeting company, raised US $18M in Seed funding. The round was led by Amplitude Ventures with participation from FTQ, Investissem... |
| 06.12.2023 | Ability Biologics Closes $12M Seed Funding | Ability Biologics, a Montreal, Canada-based premier cell targeting company, closed a $12m financing round. The round was led by founding investor Amplitude Ventures with participation from Fonds de solidarité FTQ, Charles River Laboratories... |
| - | Ability biologics | “Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.” |